Bone metastases (BM) are a major cause for morbidity in metastatic urothelial cancer (mUC) and thus it is important to evaluate the differences in clinical outcomes in mUC patients with BM and without BM. Srikala Sridhar, MD, FRCPC, of the Princess Margaret Cancer Centre, Toronto, ON, discusses results from a retrospective study investigating the impact of BM on the responses to chemotherapy in mUC patients. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
